Lilly's Imlunestrant, an Oral Serd, Significantly Improved Progression-Free Survival as Monotherapy and in Combination With Verzenio® (Abemaciclib) in Patients With Er+, Her2- Advanced Breast Cancer
Lilly的Imlunestrant,一種口服選擇性雌激素受體降解劑,顯著改善了ER+、HER2-晚期乳腺癌患者在單藥治療和與Verzenio®(阿貝馬唑)聯合治療中的無進展生存期。